PrEP

;

CVS health refusing to cover new long-acting PrEP drug

Aug 21, 2025

CVS Health’s decision is a clear violation of the ACA’s requirement to cover USPSTF-recommended preventive services, including PrEP. The entire world is excited by this drug and its potential contribution to preventing and eventually ending HIV. However, a drug will only work if people can access it and right now CVS Health, which owns the largest pharmacy benefit manager in the country, is shamefully blocking people from taking it, unlike other payers. We urge CVS, which has been committed to ending HIV in the past, to reconsider their decision immediately. Additionally, we call on federal and state regulators to ensure that plans are in compliance with the federal government’s PrEP coverage guidance and the many state laws that require coverage of all PrEP drugs.

read more

Senate Appropriators Reject Trump HIV Prevention Budget Cuts, While Maintaining Care, Treatment, and PrEP

Jul 31, 2025

Today, on a bipartisan basis, the Senate Appropriations Committee rejected the Trump administration’s proposed elimination of CDC’s HIV prevention and surveillance programs. On a vote of 26 to 3, the Committee approved the Fiscal Year 2026 Labor, HHS Appropriations bill that maintains funding for existing domestic HIV prevention along with the care, treatment, and PrEP programs that were included in the president’s budget.

read more

Supreme Court upholds preventive services coverage requirements

Jun 27, 2025

This is a great victory for healthcare in our country and for everyone who believes in prevention, including the Trump administration. This legal attack was initiated by extreme right-wing social conservatives who sought to make sure that gay men and others could not access PrEP to prevent HIV. We are very pleased the Court upheld the coverage requirement. Now we must focus on making sure insurers comply with and regulators enforce the law, particularly with new, long-acting forms of PrEP. This victory is all the more important now that the Trump administration is seeking to defund much of CDC’s HIV and hepatitis prevention programs. While we continue to oppose those proposed funding cuts, we can rest assured that at least for people with insurance, preventive services such as PrEP, HIV and hepatitis testing will be covered at no cost.

read more

FDA Approves Twice-Yearly HIV Prevention Drug

Jun 18, 2025

Today marks a monumental advance in HIV prevention. Congratulations to the many researchers who spent nineteen years to get to today’s approval, backed up by the long-term investment needed to get the drug to market. Long-acting PrEP is now not only effective for up to six months but also improves adherence and will reduce HIV infections—if people are aware of it and payers, including private insurers, cover it without cost-sharing as a preventive service.

read more

Search

Press Release Tags

ACA ADAP Appropriations Biden administration CDC Congress Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B Hepatitis C hepatits HIV HIV Prevention hous housing insurer Insurers LGBT Medicaid Medicare Part D NAIC NIH PBMs PrEP Prescription Drugs prevention Private Insurance Ryan White Ryan White Program state Syringe services Testing transparency Treatment Trump administration

Recent Press Releases

Pin It on Pinterest